Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Front Immunol. 2021 Nov 26;12:774177. doi: 10.3389/fimmu.2021.774177. eCollection 2021.
This study sought to identify the ratio of M1/M2 cells in the infrapatellar fat pads (IFP) and subcutaneous fat tissues (SC) of osteoarthritis (OA) and rheumatoid arthritis (RA) patients. The clinical features of OA and RA patients treated with or without biological disease-modifying anti-rheumatic drugs (bDMARDs) were also assessed.
IFP and SC were collected from patients with OA and RA who are undergoing total knee arthroplasty (TKA). CD14-positive cells were then isolated from these samples. Flow cytometry was used to determine the number of CD14CD80 cells and CD14CD163 cells. The expression levels of lipid transcription factors, such as sterol regulatory element-binding protein 1 (SREBP1) and liver X receptor alpha (LXRA), and inflammatory cytokines were also evaluated.
Twenty OA patients and 22 RA patients were enrolled in this study. Ten of the RA patients (45.4%) received bDAMRDs before TKA. On average, a fivefold increase in the number of CD14-positive cells and lower expression levels of and were observed in OA IFP relative to OA SC; however, these results were not obtained from the RA samples. The median ratio of CD14CD80 cells/CD14CD163 cells of OA IFP was 0.87 (0.76-1.09, interquartile range), which is higher to that of OA SC with a lower ratio ( = 0.05835).
The quantity and quality of CD14-positive cells differed between IFP and SC in arthropathy patients. To our knowledge, this is the first study to characterize the ratio of M1/M2 cells in the IFP and SC of end-stage OA and RA patients. The increased ratio of CD14CD80 cells/CD14CD163 cells in the IFP from patients with OA and RA treated with bDMARDs indicated that inflammation was localized in the IFP. As adipose tissue-derived innate immune cells were revealed as one of the targets for regulating inflammation, further analysis of these cells in the IFP may reveal new therapeutic strategies for inflammatory joint diseases.
本研究旨在确定骨关节炎（OA）和类风湿关节炎（RA）患者髌下脂肪垫（IFP）和皮下脂肪组织（SC）中 M1/M2 细胞的比例。还评估了接受或未接受生物改善病情抗风湿药物（bDMARDs）治疗的 OA 和 RA 患者的临床特征。
从接受全膝关节置换术（TKA）的 OA 和 RA 患者中采集 IFP 和 SC，然后从这些样本中分离出 CD14阳性细胞。采用流式细胞术测定 CD14CD80 细胞和 CD14CD163 细胞的数量。还评估了脂质转录因子（如固醇调节元件结合蛋白 1（SREBP1）和肝 X 受体α（LXRA））和炎症细胞因子的表达水平。
本研究纳入了 20 名 OA 患者和 22 名 RA 患者。10 名 RA 患者（45.4%）在 TKA 前接受了 bDAMRD 治疗。与 OA SC 相比，OA IFP 中 CD14 阳性细胞数量增加了五倍，和 的表达水平降低；然而，这些结果并未从 RA 样本中获得。OA IFP 中 CD14CD80 细胞/CD14CD163 细胞的中位数比值为 0.87（0.76-1.09，四分位距），高于 OA SC 的低值（=0.05835）。
在关节炎患者中，IFP 和 SC 中的 CD14 阳性细胞数量和质量不同。据我们所知，这是首次描述终末期 OA 和 RA 患者 IFP 和 SC 中 M1/M2 细胞比例的研究。接受 bDMARDs 治疗的 OA 和 RA 患者 IFP 中 CD14CD80 细胞/CD14CD163 细胞比值增加表明炎症局限于 IFP。由于脂肪组织来源的固有免疫细胞被揭示为调节炎症的靶点之一，因此对 IFP 中这些细胞的进一步分析可能为炎症性关节疾病提供新的治疗策略。
